Endpoints News poll: Let's get your opinion on that controversial aducanumab approval
If there’s one thing that’s absolutely clear in the dustup over the aducanumab approval, it’s that most everyone who can register an opinion has fired off something, somewhere. Now it’s your turn as we size up the biopharma industry’s mood on this important issue.
We’ve assembled a set of 4 questions for this industry survey gauging your opinion on the FDA’s actions involving one of the most controversial decisions the agency has ever handed down. It should only take a few minutes to complete.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.